List of Excipients in Branded Drug DICLOFENAC EPOLAMINE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Teva Pharmaceuticals USA Inc	DICLOFENAC EPOLAMINE	diclofenac epolamine	0093-3225	BUTYLENE GLYCOL
Teva Pharmaceuticals USA Inc	DICLOFENAC EPOLAMINE	diclofenac epolamine	0093-3225	CARBOXYMETHYLCELLULOSE SODIUM
Teva Pharmaceuticals USA Inc	DICLOFENAC EPOLAMINE	diclofenac epolamine	0093-3225	DIHYDROXYALUMINUM AMINOACETATE
Teva Pharmaceuticals USA Inc	DICLOFENAC EPOLAMINE	diclofenac epolamine	0093-3225	EDETATE DISODIUM
Teva Pharmaceuticals USA Inc	DICLOFENAC EPOLAMINE	diclofenac epolamine	0093-3225	GELATIN

Diclofenac Epolamine Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Diclofenac epolamine is a topical nonsteroidal anti-inflammatory drug used primarily in transdermal and topical delivery systems. The leading U.S. product, Flector 1.3% topical system, uses a drug-in-adhesive patch designed to deliver diclofenac locally for short-term treatment of acute pain from minor strains, sprains, and contusions. The principal commercial opportunity is no longer basic molecule substitution. It is differentiated delivery: lower-irritation patches, longer wear time, improved adhesion, solvent-free manufacturing, pediatric or geriatric usability, and nonprescription or international products where regulatory requirements permit.

The molecule is a small-molecule salt, not a biologic. Biosimilar competition is therefore irrelevant. Competition comes from generic diclofenac epolamine systems, alternative diclofenac salts, topical diclofenac gels, oral NSAIDs, and other topical analgesics.

What is diclofenac epolamine and how is it used?

Diclofenac epolamine is the epolamine salt of diclofenac, formulated for topical delivery. Its commercial value comes from local administration, reduced gastrointestinal exposure relative to oral NSAID therapy, and convenient application to a defined painful area.

Attribute	Diclofenac epolamine
Drug class	Nonsteroidal anti-inflammatory drug
Dosage forms	Topical patch, topical system, gel and other topical formats in selected markets
U.S. reference product	Flector 1.3% topical system
U.S. application	NDA 021234
U.S. sponsor historically associated with Flector	IBSA-related commercial operations; product ownership and distribution arrangements have changed over time
FDA approval	2007
Primary indication	Acute pain from minor strains, sprains and contusions
Regulatory pathway for generics	ANDA
Biosimilar exposure	None
Main competitive products	Diclofenac sodium gel, diclofenac sodium topical solution, oral NSAIDs, lidocaine patches and other topical analgesics

Flector is applied twice daily, with one topical system to the most painful area. The label limits use to a short treatment period and includes class-wide NSAID warnings relating to cardiovascular, gastrointestinal, renal, hepatic and dermatologic risks.[1]

What excipients are used in the Flector diclofenac epolamine patch?

The Flector system is a drug-in-adhesive topical patch. The adhesive layer contains diclofenac epolamine with gelatin, povidone and sorbitan monooleate. The system also uses a polyester backing and a fluoropolymer-coated release liner.[1]

Functional component	Reported or strategically relevant material	Function
Active ingredient	Diclofenac epolamine	Anti-inflammatory and analgesic agent
Adhesive matrix	Pressure-sensitive adhesive system	Holds the patch to skin and controls drug contact
Gelatin	Matrix or adhesive component	Film formation, structure and formulation support
Povidone	Polymer and solubilization aid	Supports dispersion and drug-polymer interactions
Sorbitan monooleate	Surfactant or wetting aid	Improves uniformity and interfacial compatibility
Backing	Polyester support	Prevents drug loss and provides mechanical integrity
Release liner	Fluoropolymer-coated liner	Protects the adhesive before application

The excipient strategy is important because diclofenac epolamine must remain uniformly distributed in a thin adhesive matrix while maintaining drug release, adhesion and skin tolerability. The formulation cannot be optimized for drug loading alone. A patch that releases drug efficiently but lifts from skin, causes irritation or leaves adhesive residue has limited commercial value.

How should an excipient strategy be designed for diclofenac epolamine?

A successful excipient program should treat the patch as an integrated drug-device system. The key development variables are drug solubility, crystallization control, adhesive rheology, skin permeation, moisture handling, peel strength and residual drug content.

1. Control drug crystallization

Diclofenac epolamine may interact with polymers, surfactants and residual solvents in ways that affect solid-state stability. A formulation should be screened for:

• Drug crystallization during storage
• Salt dissociation or conversion
• Changes in adhesive viscosity
• Drug migration into the backing or release liner
• Loss of content uniformity
• Changes in in vitro release

Povidone or related polymeric excipients can help maintain drug dispersion, but polymer grade and molecular weight must be selected carefully. Excess polymer can reduce release or increase matrix viscosity.

2. Improve adhesive performance

The commercial target is reliable adhesion during normal movement, sweating and moderate flexing. Candidate systems may include acrylic, silicone or rubber-based pressure-sensitive adhesives. Acrylic systems are attractive for solvent or hot-melt processing and can provide broad formulation flexibility. Silicone systems may improve removal characteristics and skin compatibility but can create drug-solubilization and manufacturing challenges.

Important tests include:

• Initial tack
• Peel adhesion
• Shear resistance
• Adhesion after sweating
• Adhesion during flexion
• Residual adhesive on skin
• Reapplication behavior
• Wear performance over the labeled period

A higher-tack adhesive is not automatically better. Excessive tack can increase skin stripping and discourage repeat use.

3. Reduce skin irritation

Diclofenac products are exposed to a large skin surface for extended periods. Excipient selection should minimize irritation from surfactants, residual solvents, tackifiers and low-molecular-weight extractables.

Potential approaches include:

• Lower surfactant concentrations
• Solvent-free or low-residual-solvent manufacturing
• Controlled adhesive acidity
• Reduced occlusion
• Hypoallergenic backing and liner materials
• Adhesive compositions that limit skin stripping during removal

The formulation should be tested in irritation and sensitization studies under the intended wear conditions. A patch designed for older adults may need particular focus on fragile or dry skin.

4. Improve drug release and skin delivery

Topical diclofenac performance depends on the balance between drug activity in the adhesive, release from the matrix and permeation through the stratum corneum. Candidate excipients include penetration enhancers, cosolvents, surfactants and polymeric release modifiers.

Commercially attractive strategies include:

• Higher skin flux without increasing total drug content
• More consistent delivery across different skin types
• Reduced lag time
• Longer delivery over a 12- or 24-hour period
• Lower variability after exposure to heat and humidity

Penetration enhancers may increase irritation and systemic exposure. Their use therefore requires pharmacokinetic and safety controls, not only permeation testing.

What formulations are protected by diclofenac epolamine patents?

The historical intellectual-property position around Flector has centered on the topical system, adhesive matrix, delivery architecture and related manufacturing concepts rather than on the basic diclofenac molecule. Diclofenac itself is an old active pharmaceutical ingredient, and salt selection alone generally provides weaker protection than a well-defined formulation or device claim.

Potentially relevant claim categories include:

1. Diclofenac epolamine in a pressure-sensitive adhesive matrix.
2. Specific polymer, surfactant and solvent combinations.
3. Multilayer patch construction.
4. Backing and release-liner configurations.
5. Defined drug loading and release profiles.
6. Manufacturing methods that produce uniform drug distribution.
7. Topical treatment methods using a specified dose, wear period or anatomical site.

FDA Orange Book protection is product-specific. Patent listing, expiration and delisting information must be assessed against the current Orange Book entry for NDA 021234 and any relevant ANDAs.[2] Because the Flector reference product was approved in 2007, its original three-year new-drug exclusivity period has expired. Generic applicants therefore compete through the ANDA pathway, subject to any unexpired listed patents and regulatory exclusivity that remain relevant.

When does diclofenac epolamine lose exclusivity?

The principal U.S. regulatory exclusivity period associated with Flector has already expired. Flector is not protected by biologic exclusivity, and the molecule does not receive new chemical entity exclusivity because diclofenac was previously approved.

Exclusivity or protection type	Status for Flector
New chemical entity exclusivity	Not applicable
Three-year new dosage-form exclusivity	Expired
Pediatric exclusivity	No broadly material pediatric exclusivity identified for the core product
Orphan exclusivity	Not applicable
Biosimilar exclusivity	Not applicable
Listed-patent protection	Must be checked against current FDA Orange Book records
Generic pathway	ANDA, including potential Paragraph IV certification

The commercial question is therefore patent scope and enforceability, not basic regulatory exclusivity.

What Paragraph IV challenges and generic entry risks exist?

A generic applicant may file an ANDA with a Paragraph IV certification asserting that an Orange Book-listed patent is invalid, unenforceable or not infringed. A Paragraph IV notice can trigger patent litigation and a potential 30-month stay under the Hatch-Waxman framework.[3]

For diclofenac epolamine, generic risk is concentrated in four areas:

• Direct copies of the patch with equivalent active and inactive ingredients
• Alternative adhesives that preserve the same labeled performance
• Generic systems relying on bioequivalence and comparative adhesion data
• Products that avoid narrow formulation or process claims

The main litigation risk depends on whether any listed patent covers the commercial patch broadly or only a narrow excipient combination. A patent limited to one polymer or surfactant combination may be easier to design around than a claim covering the full drug-in-adhesive architecture.

A generic launch could occur under several scenarios:

Launch scenario	Commercial effect
No enforceable listed patents	Immediate or near-immediate generic competition after ANDA approval
Paragraph IV litigation with 30-month stay	Delayed launch while infringement and validity claims are litigated
Paragraph III certification	Launch after patent expiration
Authorized generic	Earlier price pressure without an independent generic challenger
Formulation-specific patent survives	Delayed competition for the protected patch design, but possible substitution by other topical diclofenac products

What FDA regulatory status does diclofenac epolamine have?

Flector is an FDA-approved prescription topical system. The FDA label identifies systemic NSAID warnings, application restrictions, contraindications and handling instructions.[1] The product is not an OTC medicine in the United States merely because topical administration may reduce some systemic exposure.

A new diclofenac epolamine product could use several regulatory routes:

ANDA

An ANDA is the most direct path for a product that can demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. For a patch, the development package may require careful attention to adhesive performance, residual drug, release testing and comparative characterization.

505(b)(2) NDA

A 505(b)(2) application may be appropriate for a materially different formulation, delivery system, strength, dosing schedule or indication that relies in part on existing FDA findings. This route is commercially relevant for a longer-wear patch, an improved adhesive, a new gel or a different topical delivery platform.

OTC switch

An OTC strategy would require FDA agreement that consumers can use the product safely and effectively without professional supervision. NSAID warnings, treatment duration and application-site limitations make this a higher regulatory hurdle than a simple label conversion.

How strong is the patent estate for diclofenac epolamine?

The patent estate is strongest when it protects a complete product architecture rather than a single conventional excipient. A defensible estate could include:

• Composition claims covering the diclofenac epolamine adhesive matrix
• Dependent claims covering polymer ratios and surfactant levels
• Patch construction claims
• Manufacturing claims for solvent removal and uniform loading
• Use claims tied to treatment duration and application frequency
• Analytical specifications linked to release and adhesion

The estate is weaker when claims depend on common topical-patch materials that competitors can replace without changing the clinical use. Broad claims directed only to diclofenac in a topical patch face greater invalidity and design-around pressure because topical diclofenac delivery is well established.

What commercial opportunities exist for diclofenac epolamine?

Premium generic patch

A generic patch can compete on price, but a differentiated generic may command better margins through:

• Improved adhesion
• Reduced skin irritation
• Lower residue
• Easier liner removal
• Smaller patch size
• Longer wear
• Better packaging for moisture protection

Extended-wear product

Flector is used twice daily. A 12-hour or 24-hour product could offer a meaningful convenience benefit if exposure and safety remain acceptable. The product would likely require comparative pharmacokinetic, adhesion and local-tolerability data.

Pediatric and geriatric formats

Pediatric use would require a dedicated safety and dosing strategy. The geriatric market may be more commercially accessible because older patients have a high prevalence of musculoskeletal pain and difficulty swallowing oral medicines. A smaller, easier-to-handle patch could support a 505(b)(2) strategy or a differentiated generic position.

International licensing

Diclofenac topical products have broad global acceptance, but regulatory classifications differ. Licensing opportunities may involve:

• Regional rights for patches
• Local manufacturing and packaging
• Co-development of gels or medicated plasters
• OTC products in jurisdictions with established topical diclofenac monographs
• Hospital or pharmacy-channel products

Any licensing valuation should separate rights to the active ingredient, formulation technology, regulatory dossier and brand.

Combination products

Potential combinations include diclofenac epolamine with counterirritants, cooling agents or local anesthetics. These products increase formulation and regulatory complexity. They also create greater interaction risk, particularly for skin irritation and permeation.

Manufacturing platform licensing

Solvent-free coating, precision hot-melt processing, continuous mixing and multilayer lamination technologies may have value beyond diclofenac. A platform patent covering manufacturing performance can support licensing across other topical NSAIDs and analgesics.

How does diclofenac epolamine compare with diclofenac sodium topical products?

Factor	Diclofenac epolamine patch	Diclofenac sodium gel or solution
Application	Preformed topical system	User-applied dose
Dosing consistency	Generally higher	Depends on measuring and rubbing
Adhesion risk	Central product attribute	Not applicable
Residue	Adhesive residue possible	Gel or solution residue possible
Excipient focus	Adhesive, backing, liner and release	Solvent, gel former, penetration enhancer
Commercial differentiation	Wear time, adhesion and skin comfort	Absorption, drying, feel and package design
Generic complexity	Patch characterization and device performance	Semi-solid or solution equivalence
Patient convenience	High after application	Requires repeated application and dosing measurement

Diclofenac epolamine is most attractive where controlled application and convenience justify a premium over gels. Diclofenac sodium gel may be more competitive in markets where low price and broad OTC access dominate.

What patent litigation and settlement issues affect the market?

Patent litigation is most likely when a generic applicant files a Paragraph IV certification against a listed formulation or system patent. Settlement agreements may include delayed generic launch dates, authorized-generic arrangements, licenses, supply agreements or restrictions on product design.

Publicly assessable commercial conclusions should be based on:

• Current Orange Book listings
• FDA ANDA approvals
• Federal district court dockets
• Paragraph IV notice records
• Settlement filings submitted to the Federal Trade Commission and Department of Justice
• Marketed product labeling

A settlement that permits entry before patent expiration can materially reduce expected brand revenue even if the patent remains technically valid. Conversely, a narrow settlement may allow a non-infringing generic to launch with a redesigned adhesive.

What revenue exposure and competitive landscape should investors assess?

Revenue exposure depends on the size of the patch market, the degree of substitution by diclofenac gels, payer coverage, generic timing and brand retention. Flector’s commercial value is more vulnerable to generic substitution than a product with a protected delivery platform or strong device barrier.

Key commercial indicators include:

• Annual U.S. prescriptions
• Net price after rebates
• Generic share
• Payer step-edit requirements
• Retail versus specialty distribution
• International sales by country
• Patch manufacturing capacity
• Number of approved or pending ANDAs
• Price differential versus diclofenac gel
• Brand retention after generic entry

A company with a proprietary adhesive or coating platform may generate greater long-term value by licensing the technology across multiple topical products rather than relying on diclofenac epolamine alone.

Key Takeaways

• Diclofenac epolamine is a small-molecule topical NSAID with no biosimilar risk.
• Flector 1.3% is a drug-in-adhesive patch using gelatin, povidone and sorbitan monooleate with polyester and fluoropolymer support materials.
• The main formulation challenges are crystallization control, adhesion, skin tolerability, release consistency and manufacturing uniformity.
• U.S. regulatory exclusivity has expired; commercial protection depends on current listed patents, formulation claims and product differentiation.
• The strongest opportunities are premium generics, longer-wear patches, lower-irritation systems, geriatric-friendly formats and international licensing.
• Generic entry risk is substantial because diclofenac is an established active and alternative topical formulations are available.
• A defensible patent estate should cover the adhesive matrix, patch construction, process controls and measurable product performance.

FAQs

Is diclofenac epolamine the same as diclofenac sodium?

No. Both deliver diclofenac, but they are different salts. Diclofenac epolamine is commonly used in topical systems, while diclofenac sodium is widely used in gels, solutions, tablets and other dosage forms.

Can diclofenac epolamine be developed as an OTC patch?

Potentially, but an OTC switch would require FDA support for safe consumer-directed use. Treatment duration, NSAID warnings, application restrictions and misuse risk would be central regulatory issues.

Which excipient is most important in a diclofenac epolamine patch?

No single excipient determines performance. The pressure-sensitive adhesive system is the most commercially important component because it controls adhesion, release, skin contact and user experience.

Does a diclofenac epolamine patch require bioequivalence testing?

A generic patch must demonstrate equivalence through the applicable FDA requirements for topical systems. Testing may include product characterization, drug release, adhesion, irritation, pharmacokinetics or other studies specified by FDA guidance and the product-specific regulatory framework.

Is a smaller diclofenac epolamine patch commercially attractive?

Yes, if it maintains adequate local exposure and adhesion. A smaller patch could reduce material use, improve comfort, lower manufacturing cost and support differentiation, but it would require comparative performance and clinical justification.

References

1. U.S. Food and Drug Administration. (2023). Flector (diclofenac epolamine) topical system prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2019). ANDA submissions: Refuse-to-receive standards. FDA.

4. U.S. Food and Drug Administration. (2023). Product-specific guidance for generic drug development: Diclofenac epolamine topical system. FDA.

5. U.S. Food and Drug Administration. (2024). Approved drug product labeling and application records for NDA 021234. FDA.